Biotech sector slips amid reported return of ousted FDA official
Source: SeekingAlpha
2025-08-11 06:25:01 ET
More on Sarepta Therapeutics, Capricor Therapeutics, Inc., etc.
- Replimune Group: The Prospects For FDA Approval After Rejection
- Sarepta Therapeutics: Beaten Down, But Not Out
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Capricor rises as FDA meeting renews hopes for rejected cell therapy
- Sarepta Therapeutics Q2 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Biotech sector slips amid reported return of ousted FDA official
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
3.76% G/L:
$8.41 Last:
3,185,142 Volume:
$7.70 Open:
REPL Latest News
February 03, 2026 08:00:00 am
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
December 18, 2025 08:00:00 am
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
